Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed 180 enrolled M.D. Anderson Cancer Center Celgene Corporation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied.

Timeline

Start: 2010-08
Primary completion: 2016-05
Completion: 2016-05

Publications

Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr;32(2):279-86. doi: 10.1007/s10637-013-9966-3. Epub 2013 Jun 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Lenalidomide	Other / unclassified	5 mg	Oral
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Subject	Leucovorin	Small molecule	400 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	65 mg/m2	Intravenous
Subject	Sorafenib	Small molecule	200 mg	Oral
Subject	Temsirolimus	Small molecule	15 mg	Intravenous
Subject	fluorouracil	Small molecule	400 mg/m2	Intravenous

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Summary

Timeline

Publications

Drugs

Indications